Since the role of IL-6 and IL-17 has been shown to activate multiple signaling pathways important for cancer development, the differentiation of anti-inflammatory subsets is responsible for stabilizing the phenotype of tumor suppressors. This evidence concerns the gene IL17A and cancer.